Suchergebnisse - "Brown, Jennifer R"

PubPharm (7)

1

Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA) : a randomised, controlled, phase 3 trial

enthalten in: The Lancet. Oncology | 2022

von Tam, C. | Brown, J. | Kahl, B. | +28

CommentIn: Lancet Oncol. 2022 Aug;23(8):965-967. - PMID 35810752

2

PI3K inhibitors in haematological malignancies

enthalten in: The Lancet. Oncology | 2022

von Brown, J. | Danilov, A. | LaCasce, A. | +1

CommentOn: Lancet Oncol. 2022 May;23(5):563-566. - PMID 35429996

3

Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia : a single-arm, open-label, phase 2 study

enthalten in: The Lancet. Oncology | 2021

von Davids, M. | Lampson, B. | Tyekucheva, S. | +15

4

Ibrutinib : searching for a partner drug

enthalten in: The Lancet. Oncology | 2019

von Kater, A. | Brown, J.

5

Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia : interim results from a phase 3, randomised, double-blind, placebo-controlled trial

enthalten in: The Lancet. Oncology | 2017

von Zelenetz, A. | Barrientos, J. | Brown, J. | +20

CommentIn: Lancet Oncol. 2017 Mar;18(3):270-271. - PMID 28139406

6

Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17) : a phase 2, open-label, multicentre study

enthalten in: The Lancet. Oncology | 2016

von O'Brien, S. | Jones, J. | Coutre, S. | +18

CommentIn: Lancet Oncol. 2016 Oct;17 (10 ):1342-1343. - PMID 27637986

7

A new era of treatment for chronic lymphocytic leukaemia?

enthalten in: The Lancet. Oncology | 2014

von Brown, J.

CommentOn: Lancet Oncol. 2014 Jan;15(1):48-58. - PMID 24332241

1
[1]